Vis enkel innførsel

dc.contributor.authorHailu, Alemayehu
dc.contributor.authorEregata, Getachew Teshome
dc.contributor.authorYigezu, Amanuel
dc.contributor.authorBertram, Melanie
dc.contributor.authorJohansson, Kjell Arne
dc.contributor.authorNorheim, Ole Frithjof
dc.date.accessioned2022-02-02T13:34:13Z
dc.date.available2022-02-02T13:34:13Z
dc.date.created2021-09-29T16:45:55Z
dc.date.issued2021
dc.identifier.issn1478-7547
dc.identifier.urihttps://hdl.handle.net/11250/2976684
dc.description.abstractBackground Cost-effectiveness of interventions was a criterion decided to guide priority setting in the latest revision of Ethiopia’s essential health services package (EHSP) in 2019. However, conducting an economic evaluation study for a broad set of health interventions simultaneously is challenging in terms of cost, timeliness, input data demanded, and analytic competency. Therefore, this study aimed to synthesize and contextualize cost-effectiveness evidence for the Ethiopian EHSP interventions from the literature. Methods The evidence synthesis was conducted in five key steps: search, screen, evaluate, extract, and contextualize. We searched MEDLINE and EMBASE research databases for peer-reviewed published articles to identify average cost-effectiveness ratios (ACERs). Only studies reporting cost per disability-adjusted life year (DALY), quality-adjusted life year (QALY), or life years gained (LYG) were included. All the articles were evaluated using the Drummond checklist for quality, and those with a score of at least 7 out of 10 were included. Information on cost, effectiveness, and ACER was extracted. All the ACERs were converted into 2019 US dollars using appropriate exchange rates and the GDP deflator. Results In this study, we synthesized ACERs for 382 interventions from seven major program areas, ranging from US$3 per DALY averted (for the provision of hepatitis B vaccination at birth) to US$242,880 per DALY averted (for late-stage liver cancer treatment). Overall, 56% of the interventions have an ACER of less than US$1000 per DALY, and 80% of the interventions have an ACER of less than US$10,000 per DALY. Conclusion We conclude that it is possible to identify relevant economic evaluations using evidence from the literature, even if transferability remains a challenge. The present study identified several cost-effective candidate interventions that could, if scaled up, substantially reduce Ethiopia’s disease burden.en_US
dc.language.isoengen_US
dc.publisherBMCen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleContextualization of cost-efectiveness evidence from literature for 382 health interventions for the Ethiopian essential health services package revisionen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright The Author(s) 2021en_US
dc.source.articlenumber58en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1186/s12962-021-00312-5
dc.identifier.cristin1940818
dc.source.journalCost Effectiveness and Resource Allocationen_US
dc.identifier.citationCost Effectiveness and Resource Allocation. 2021, 19, 58.en_US
dc.source.volume19en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal